Biopsy-Negative Rejection Late after Heart Transplantation: Impact on Long-Term Outcome

2019 ◽  
Vol 38 (4) ◽  
pp. S287-S288
Author(s):  
A. Wolfson ◽  
M. Kittleson ◽  
J. Patel ◽  
E. Kransdorf ◽  
R. Cole ◽  
...  
2011 ◽  
Vol 59 (S 01) ◽  
Author(s):  
J Sindermann ◽  
I Alejnik ◽  
J Hoffmann ◽  
S Klotz ◽  
A Löher ◽  
...  

2005 ◽  
Vol 53 (1) ◽  
pp. S121.5-S122
Author(s):  
N. P. Almeda ◽  
J. Odim ◽  
H. Laks ◽  
J. K. Patel ◽  
M. Hamilton ◽  
...  

Author(s):  
N. N. Koloskova ◽  
V. N. Poptsov ◽  
A. О. Shevchenko

Heart transplantation is the «gold standard» of treatment severe heart failure. Immunosuppressive therapy aimed at the prevention of acute allograft rejection is the cornerstone of post-transplant management. In addition to its direct effects, immunosuppressive therapy is also involved in the generation of a number of post-transplant morbidities that limit the long-term outcome of heart transplant recipients. Given these data it appears that the individual tailoring of immunosuppressive therapy is of paramount importance in determining the outcome of heart transplantation. The goal of immunosuppressive therapy is to prevent rejection of the transplanted heart, while minimizing drug-related effects, such as infection, malignancy, diabetes, hypertension, and renal insuffi ciency. This review aimed is to analyze the protocols for the appointment of immunosuppressive therapy in various groups of recipients after heart transplantation.


Sign in / Sign up

Export Citation Format

Share Document